Odelaisy León-Triana

Ms. Odelaisy León-Triana


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Communications in Nonlinear Science and Numerical Simulation
Verified
Journal Article
Closed access
OLOdelaisy León-Triana
Odelaisy León-Triana
SSSoukaina Sabir
Soukaina Sabir
Gabriel Fernandez CalvoGabriel Fernandez Calvo
Gabriel Fernandez Calvo
Juan Belmonte-BeitiaJuan Belmonte-Beitia
Juan Belmonte-Beitia
Salvador ChuliánSalvador Chulián
Salvador Chulián
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García

9 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
OLOdelaisy León-Triana
Odelaisy León-Triana
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez
MRManuel Ramírez
Manuel Ramírez
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Chimeric antigen receptor (CAR)-T cell-based therapies have achieved substantial success against B-cell malignancies, which has led to a growing scientific and clinical interest in extending their use to solid cancers. However, results for solid tumours have been limited up to now, in part due to the immunosuppressive tumour microenvironment, which is able to inactivate CAR-T cell clones. In this paper we put forward a mathematical model describing the competition of CAR-T and tumour cells, taking into account their immunosuppressive capacity. Using the mathematical model, we show that the use of large numbers of CAR-T cells targetting the solid tumour antigens could overcome the immunosuppressive potential of cancer. To achieve such high levels of CAR-T cells we propose, and study computationally, the manufacture and injection of CAR-T cells targetting two antigens: CD19 and a tumour-associated antigen. We study in silico the resulting dynamics of the disease after the injection of this product and find that the expansion of the CAR-T cell population in the blood and lymphopoietic organs could lead to the massive production of an army of CAR-T cells targetting the solid tumour, and potentially overcoming its immune suppression capabilities. This strategy could benefit from the combination with PD-1 inhibitors and low tumour loads. Our computational results provide theoretical support for the treatment of different types of solid tumours using T cells engineered with combination treatments of dual CARs with on- and off-tumour activity and anti-PD-1 drugs after completion of classical cytoreductive treatments.

26 March 2021 in Mathematics
Verified
Journal Article
Open access
PDF file
OLOdelaisy León-Triana
Odelaisy León-Triana
JPJulián Pérez-Beteta
Julián Pérez-Beteta
JLJosé David Albillo Labarra
José David Albillo Labarra
Ana Ortiz de MendivilAna Ortiz de Mendivil
Ana Ortiz de Mendivil
Luis Pérez-RomasantaLuis Pérez-Romasanta
Luis Pérez-Romasanta
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Brain metastases (BMs) are cancer cells that spread to the brain from primary tumors in other organs. Up to 35% of adult cancer patients develop BMs. The treatment of BM patients who have well-controlled extracranial disease and a small number of lesions consists of localized doses of radiation (stereotactic radio surgery (SRS)). Estimating prognosis among BM patients may allow treatments to be chosen that balance durability of intracranial tumor control with quality of life and the side effects of treatment. No mathematical model-based quantitative biomarkers have been determined for estimating prognosis. As a first step toward that goal, we describe a mathematical model of growth and response of brain metastasis to stereotactic radio surgery. The mathematical model incorporates some biological mechanisms involved in BM growth and response to SRS and allows the observed dynamics to be accurately described.

30 May 2018 in Journal of The Royal Society Interface
Verified
Journal Article
Closed access
PDF file
OLOdelaisy León-Triana
Odelaisy León-Triana
Gabriel Fernandez CalvoGabriel Fernandez Calvo
Gabriel Fernandez Calvo
Juan Belmonte-BeitiaJuan Belmonte-Beitia
Juan Belmonte-Beitia
MDM. Rosa Durán
M. Rosa Durán
JEJ. Escribano-Serrano
J. Escribano-Serrano
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Diabetes mellitus constitutes a major health problem and its clinical presentation and progression may vary considerably. A number of standardized diagnostic and monitoring tests are currently used for diabetes. They are based on measuring either plasma glucose, glycated haemoglobin or both. Their main goal is to assess the average blood glucose concentration. There are several sources of interference that can lead to discordances between measured plasma glucose and glycated haemoglobin levels. These include haemoglobinopathies, conditions associated with increased red blood cell turnover or the administration of some therapies, to name a few. Therefore, there is a need to provide new diagnostic tools for diabetes that employ clinically accessible biomarkers which, at the same time, can offer additional information allowing us to detect possible conflicting cases and to yield more reliable evaluations of the average blood glucose level concentration. We put forward a biomathematical model to describe the kinetics of two patient-specific glycaemic biomarkers to track the emergence and evolution of diabetes: glycated haemoglobin and its labile fraction. Our method incorporates erythrocyte age distribution and utilizes a large cohort of clinical data from blood tests to support its usefulness for diabetes monitoring.

7 December 2020 in Preprints.org
Verified
Preprint
Open access
OLOdelaisy León-Triana
Odelaisy León-Triana
APAntonio Pérez-Martínez
Antonio Pérez-Martínez
MRManuel Ramírez
Manuel Ramírez
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Chimeric antigen receptor (CAR)-T cell-based therapies have achieved substantial successes against B-cell malignancies, what has led to a growing scientific and clinical interest on extending their use to solid cancers. However, results for solid tumours have been limited up to now, in part due to the immuno-suppressive tumour microenvironment, that is able to inactivate CAR-T cell clones. In this paper we put forward a mathematical model describing the competition of CAR-T and tumour cells, accounting for their immunosuppressive capabilities. Using the mathematical model, we show that the use of large numbers of CAR-T cells targeting the solid tumour antigens could overcome the cancer immunosuppressive potential. To achieve such high levels of CAR-T cells we propose and study computationaly, the manufacture and injection of CAR-T cells targeting two antigens: CD19 and a tumour-associated antigen. We study in-silico the resulting dynamics of the disease after the injection of this product and find that the expansion of the CAR-T cell population in the blood and lymphopoietic organs could lead to the massive generation of an army of CAR-T cells targetting the solid tumour, and potentially overcoming its inmune suppression capabilities. That strategy could benefit from the combination with PD-1 inhibitors and of low tumour loads. Our computational results provide a theoretical support for the treatment of different types of solid tumours using T-cells engineered with combination treatments of dual CARs with on- and off-tumour activity and anti-PD1 drugs after completion of classical cytoreductive treatments.

4 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
BOBeatriz Ocaña-Tienda
Beatriz Ocaña-Tienda
JPJulián Pérez-Beteta
Julián Pérez-Beteta
DMDavid Molina-García
David Molina-García
JJJuán Jiménez-Sánchez
Juán Jiménez-Sánchez
OLOdelaisy León-Triana
Odelaisy León-Triana
Víctor M. Pérez-GarcíaVíctor M. Pérez-García
Víctor M. Pérez-García
Tumor growth is the result of the interplay of complex biological processes in huge numbers of individual cells living in changing environments. Effective simple mathematical laws have been shown to describe tumor growth in vitro, or simple animal models with bounded-growth dynamics accurately. However, results for the growth of human cancers in patients are scarce. Our study mined a large dataset of 1133 brain metastases (BMs) with longitudinal imaging follow-up to find growth laws for untreated BMs and recurrent treated BMs. Untreated BMs showed high growth exponents, most likely related to the underlying evolutionary dynamics, with experimental tumors in mice resembling accurately the disease. Recurrent BMs growth exponents were smaller, most probably due to a reduction in tumor heterogeneity after treatment, which may limit the tumor evolutionary capabilities. In silico simulations using a stochastic discrete mesoscopic model with basic evolutionary dynamics led to results in line with the observed data.